Article Figures & Data
Figures
- Figure 1 Frequency and Absolute Number of MCAM+ mTh Cells Increased in Patients With NMOSD
(A.a–A.c) Representative dot plot and histogram of MCAM+ (CD146+) mTh cells (CD3+ CD4+ CD45RA− lymphocytes) using flow cytometry. The lymphocyte subsets included mTh cells, CD3+ CD4+ CD45RA− lymphocytes; naive helper T cells, CD3+ CD4+ CD45RA+ lymphocytes; CD8+ T cells, CD3+ CD8+ lymphocytes; and B cells, CD3− CD19+ lymphocytes. The MCAM+ (CD146+) and α4-integrin+ (CD49d+) populations were defined based on the fluorescence intensity of the isotype control. (B) Frequency of MCAM+ cells in all lymphocyte subsets (n = 183: 72 patients with MS, 29 with NMOSD, 23 with MG, 34 with NIND, and 25 HCs). (C.a–C.d) Frequency of MCAM+ cells in all participants (72 patients with MS, 29 with NMOSD, 23 with MG, 34 with NIND, and 25 HCs). (D.a–D.c) Absolute number of MCAM+ cells in all patients (40 patients with MS, 23 with NMOSD, 17 with MG, and 26 NIND). Dimethyl fumarate (DMF)- (n = 11) and fingolimod- (n = 18) treated patients with MS were excluded because treatment with these DMDs reduces the absolute number of lymphocytes. Dots represent individual samples. The lower, upper, and middle lines correspond to the 25th centile, 75th centile, and median, respectively. *p < 0.05, **p < 0.01, and ***p < 0.001. HC = healthy control; MCAM = melanoma cell adhesion molecule; MG = myasthenia gravis; mTh cell = memory helper T cell; NIND = noninflammatory neurologic disorders; NMOSD = neuromyelitis optica spectrum disorder; ns = not significant.
- Figure 2 Frequency and Absolute Number of MCAM+ Lymphocytes in DMD- or Steroid-Treated Patients With CNS IDD
(A.a–A.c) Frequency of MCAM+ cells in each lymphocyte subset among the DMD- or steroid-treated patients with MS (IFN-β [n = 12], DMF [n = 11], FTY [n = 18], and NTZ [n = 6]) and untreated patients with MS (n = 25). (B.a–B.c) Absolute number of MCAM+ cells in each lymphocyte subset among the DMD- or steroid-treated patients with MS (IFN-β [n = 9], DMF [n = 10], FTY [n = 18], and NTZ [n = 6]) and untreated patients (n = 24). (C) Frequency of MCAM+ mTh cells in the PB of patients with NMOSD and MG treated with or without PSL. At the time of examination, 25 of the 29 patients with NMOSD and 19 of the 23 patients with MG were undergoing treatment with oral PSL. Dots represent individual samples. The lower, upper, and middle lines correspond to the 25th centile, 75th centile, and median, respectively. *p < 0.05, **p < 0.01, and ***p < 0.001. DMD = disease-modifying drug; DMF = dimethyl fumarate; FTY = fingolimod; IDD = inflammatory demyelinating disease; IFN = interferon; MCAM = melanoma cell adhesion molecule; MG = myasthenia gravis; mTh cell = memory helper T cell; NMOSD = neuromyelitis optica spectrum disorder; ns = not significant; NTZ = natalizumab; PB = peripheral blood; PSL = prednisolone.
- Figure 3 Frequency of MCAM+ mTh Cells Was Increased in the CSF of Patients With CNS IDD
(A.a–A.c) Frequency of CSF and PB MCAM+ lymphocytes (MS [n = 10], NMOSD [n = 6], and NIND [n = 15]). At examination, 8 patients with MS and 4 patients with NMOSD were in the relapse phase. (B.a–B.b) Absolute number of CSF MCAM+ lymphocytes (MS [n = 10], NMOSD [n = 5], and NIND [n = 13]). The absolute number of MCAM+ B cells is not shown in this figure because this subset has been rarely observed in the CSF. Closed circles represent the relapse phase, and closed squares represent the remission phase in (A) and (B). (C) Correlation between the frequencies of PB and CSF MCAM+ mTh cells in patients with (C.a) NMOSD (n = 6, closed square) and NIND (n = 15, closed triangle) and (C.b) only in patients with MS (n = 10, closed circle). Dots represent individual samples. The lower, upper, and middle lines correspond to the 25th centile, 75th centile, and median, respectively. *p < 0.05, **p < 0.01, and ***p < 0.001. IDD = inflammatory demyelinating disease; MCAM = melanoma cell adhesion molecule; mTh cell = memory helper T cell; NIND = noninflammatory neurologic disorders; NMOSD = neuromyelitis optica spectrum disorder; ns = not significant; PB = peripheral blood.
Tables
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
